Clinical Trials Browser

Phase 3 × Breast Neoplasms × pembrolizumab × Clear all

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06312176 2026-03-13

MK-2870-010

Phase 3 Recruiting

1,200 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

340 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

1,902 enrolled

Breast

Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06606730 2025-08-26

OPT-PEMBRO

Phase 3 Recruiting

2,454 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

1,240 enrolled

Breast

Breast Neoplasms

Clinical Trials

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

MK-2870-010

KEYNOTE-B49

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

ADAPT-TN-III

ADAPT-TN-IV

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

OPT-PEMBRO

KEYNOTE-756